Enveric Biosciences (ENVB) Financials

$1.46

$0.00 (0.06%)

As on 11-Sep-2026 12:37EDT

Market cap

$6 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.8

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	0.15	0.20	0.34	0.41	0.44	0.68
Gross Profit	-0.15	-0.20	-0.34	-0.41	-0.44	-0.68
Operating Expenses	8.57	8.57	9.29	16.04	19.53	25.26
Operating Profit (EBIT)	-8.73	-8.77	-9.63	-16.45	-19.96	-25.94
Other Income	--	--	--	--	--	--
Profit before Tax	-8.73	-8.77	-9.57	-17.26	-19.96	-56.43
Provision for Tax	1.51	3.36	0.01	0.03	-1.49	-7.45
Profit after Tax (Net Income)	-8.73	-12.13	-9.57	-0.02	-18.50	-48.98
Minority Interest	--	--	--	-0.03	-0.03	--
Consolidated Profit	--	--	--	--	--	-48.98

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	8.08	4.18	1.59	1.96	15.56	22.31
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	--	--	--	--	2.33
Current Liabilities	0.86	0.92	1.49	2.34	4.00	2.08
Total Liabilities	9.81	5.10	3.08	4.30	19.55	26.72

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	0.15	0.16	0.35	0.72	1.12	8.98
Current Assets	8.79	4.94	2.73	3.58	18.43	17.74
Total Assets	9.81	5.10	3.08	4.30	19.55	26.72
Total Debt*	--	--	--	--	0.06	0.18
Net Current Assets	7.93	4.02	1.24	1.24	14.44	15.65

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-8.14	-7.73	-14.09	-17.15	-11.46
Cash Flow from Investing Activities	--	--	--	0.01	-0.58	2.19
Cash from Financing Activities	--	10.58	7.67	-1.34	18.18	24.90
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-9.89	-11.43	-175.37	-0.17	-180.53	-1,268.83
Cash EPS ($)	--	-11.24	-169.18	3.87	-176.28	-1,251.17
Adjusted Book Value ($)	--	3.94	29.17	19.09	151.78	577.87
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-7.67	-141.50	-137.51	-167.29	-296.83
Free Cash Flow per Share ($)	--	-7.67	-141.50	-137.56	-172.98	-319.23

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-420.48	-539.57	-0.20	-97.13	-318.25
ROE (%)	-142.40	-420.48	-539.57	-0.20	-97.74	-380.82
ROA (%)	-118.62	-296.67	-259.40	-0.14	-79.98	-317.87
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	--	--	-1.00
EBIT Growth (%)	12.15	8.30	44.59	13.48	64.64	-778.92
Net Profit Growth (%)	12.21	-26.70	-55,272.35	99.91	62.22	-613.46
EPS Growth (%)	90.28	0.93	-1,038.50	1.00	0.86	-0.81
Book Value Growth (%)	-79.93	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-0.32	0.00	-7.71	-0.01	0.00
Price / Book Value	0.76	0.92	0.01	0.07	0.01	0.00
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.29	0.10	0.24	0.13	0.89	0.31
Close Price ($)	1.38	3.63	64.51	234.00	374.40	8,370.00
High Price ($)	17.64	96.30	525.60	1,256.40	10,080.00	63,000.00
Low Price ($)	1.26	3.60	53.19	219.60	282.60	8,370.00
Market Cap ($ Cr)	6.22	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	--	--	--	0.00	0.01
Short term debt to equity ratio	--	--	--	--	0.00	0.00
Current Ratio	10.21	5.38	1.84	1.53	4.61	8.51
Quick Ratio	10.21	--	--	--	--	--
Interest Coverage	-7,799.76	-82,753.59	--	-4,655.56	-3,801.13	-5,469.31

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	1,002.66	941.85	752.85	481.18	365.63
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.